ProMIS Alzheimer's Drug Shows 4.4% ARIA Rate, No Swelling
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- ProMIS Neurosciences released interim results from an Alzheimer's clinical trial evaluating its amyloid-targeting treatment, reporting a total ARIA rate of 4.4% in a pooled blinded analysis of drug and placebo patients.
- All observed ARIA cases were mild and asymptomatic, with zero incidents of ARIA-E, the more severe side effect associated with brain swelling.
- Every reported case was classified as ARIA-H, involving only tiny brain bleeds, rather than the more dangerous swelling variant.
- The company positioned the safety profile as potentially superior to currently approved amyloid-targeting Alzheimer's therapies, which have carried higher rates of brain bleeding and swelling.
Why it matters: Approved anti-amyloid Alzheimer's treatments like Leqembi and Kisunla carry well-documented ARIA risks that have constrained their use. If ProMIS's interim safety signal holds in larger trials, it could open a path to a drug with fewer of the brain-swelling and bleeding complications that have limited uptake of the existing class.
